Mineralys Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Mineralys Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($36.93M) | Nov 10, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($43.27M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($43.27M) | Aug 12, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($42.21M) | Nov 10, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($42.21M) | May 12, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($42.21M) | Aug 12, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($56.34M) | Nov 10, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($41.01M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($41.01M) | Aug 12, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($31.51M) | Aug 12, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($31.51M) | Nov 10, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($31.51M) | May 12, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($22.76M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($12.14M) | Aug 13, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($12.14M) | Nov 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($12.61M) | May 9, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($12.61M) | Aug 13, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($12.61M) | Nov 12, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($6.68M) | Nov 7, 2023 |
| Q3 | 2023 | Jun 30, 2022 | ($6.48M) | Nov 7, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($41.13M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($46.75M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($44.45M) | May 12, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($60.11M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($45.17M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($35.36M) | May 12, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($26.27M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($15.74M) | Aug 13, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($14.94M) | May 9, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($7.42M) | Nov 7, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($6.48M) | Aug 7, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($7.57M) | May 15, 2023 |